Merck Highlights Early Tiespectus Data - Top-Institutions - MDSpire

Merck Highlights Early Tiespectus Data

At the ASRS meeting in Montreal, Baruch D. Kuppermann, MD, PhD, presented BRVO findings from the phase 1/2a RIOJA program evaluating the investigational VEGF/Tie2 bispecific.

  • By

  • Jim Gallagher, senior managing editor

  • July 15, 2026

  • 3 min

Share

Top Institutions in Ophthalmology

Brief introduction explaining scope and methodology.

  • #1

    Gavin Herbert Eye Institute
    Gavin Herbert Eye Institute

    Irvine, California

    Key Differentiators

    • Ophthalmology

  • #2

    University of California, Irvine
    University of California, Irvine

    Irvine, California

    Key Differentiators

    • Ophthalmology

  • #3

    Macula Society
    Macula Society

    N/A, N/A

    Key Differentiators

    • Ophthalmology

  • #4

    New York Eye and Ear Infirmary of Mount Sinai
    New York Eye and Ear Infirmary of Mount Sinai

    New York, New York

    Key Differentiators

    • Ophthalmology

  • #5

    DRCR Retina Network
    DRCR Retina Network

    N/A, N/A

    Key Differentiators

    • Ophthalmology

Original Source(s)

Merck Highlights Early Tiespectus Data

  • by Jim Gallagher, senior managing editor

  • July 15, 2026

Related Content

Diagnostic accuracy and clinical performance of deep learning models for grading diabetic retinopathy: a systematic review and meta-analysis

Marked and reversible circulating insulin-like growth factor-1 elevation during teprotumumab N01 treatment for thyroid eye disease with limited correspondence to glycemic changes

A First Look at Phase 2 ArMaDa Data

Arshad M. Khanani, MD, FASRS, discusses phase 2 findings for OCU410, an investigational gene therapy for geographic atrophy. A phase 3 program is expected to begin later this year.